FIA
CORT icon

FNY Investment Advisers’s Corcept Therapeutics CORT Stock Holding History

FNY Investment Advisers’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-1,000
Closed -$32K – 696
2023
Q4 		$32K Buy
+1,000
New +$27.5K 0.04% 223

Other funds holding CORT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $5.56B AUM 17.89% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

FNY Investment Advisers's CORT Position: Q1 2024 in Review

FNY Investment Advisers sold out of Corcept Therapeutics (CORT) in Q1 2024, closing a stake of 1,000 shares — an estimated $32K sold.

FNY Investment Advisers first reported a position in CORT in Q4 2023 and held it in 1 quarter. The position peaked at $32K in Q4 2023. 287 funds tracked by Wall St. Rank hold CORT as of Q1 2024.

  • FNY Investment Advisers reported no remaining Corcept Therapeutics position as of Q1 2024 after selling out during the quarter.
  • FNY Investment Advisers sold 1,000 Corcept Therapeutics shares in Q1 2024, an estimated $32K.
  • FNY Investment Advisers first reported a position in Corcept Therapeutics in Q4 2023 and held it in 1 quarter.
  • FNY Investment Advisers's Corcept Therapeutics position peaked at $32K in Q4 2023.
  • 287 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q1 2024.

Based on FNY Investment Advisers's 13F filing for Q1 2024, filed 3 May 2024.